(-0.08%) 5 304.25 points
(-0.09%) 40 140 points
(-0.05%) 18 465 points
(-0.07%) $83.11
(-0.62%) $1.752
(0.73%) $2 254.80
(0.74%) $25.10
(0.21%) $923.00
(0.05%) $0.927
(0.19%) $10.86
(0.06%) $0.793
(-0.27%) $92.33
Live Chart Being Loaded With Signals
AlzeCure Pharma AB (publ), a pharmaceutical company, develops drug therapies for the treatment of severe diseases and conditions that affect the central nervous system...
Stats | |
---|---|
Today's Volume | 172 453 |
Average Volume | 51 485.00 |
Market Cap | 113.00M |
EPS | SEK0 ( 2024-02-26 ) |
Next earnings date | ( SEK0 ) 2024-05-02 |
Last Dividend | SEK0 ( N/A ) |
Next Dividend | SEK0 ( N/A ) |
P/E | -2.80 |
ATR14 | SEK0.0210 (1.15%) |
Volume Correlation
AlzeCure Pharma AB (publ) Correlation
10 Most Positive Correlations |
---|
10 Most Negative Correlations |
---|
Did You Know?
Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).
Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.
AlzeCure Pharma AB (publ) Correlation - Currency/Commodity
AlzeCure Pharma AB (publ) Financials
Annual | 2022 |
Revenue: | SEK0 |
Gross Profit: | SEK-570 000 (0.00 %) |
EPS: | SEK-1.170 |
Q3 | 2023 |
Revenue: | SEK0 |
Gross Profit: | SEK-109 000 (0.00 %) |
EPS: | SEK-0.120 |
Q2 | 2023 |
Revenue: | SEK0 |
Gross Profit: | SEK-125 000 (0.00 %) |
EPS: | SEK-0.160 |
Q1 | 2023 |
Revenue: | SEK0 |
Gross Profit: | SEK-132 000 (0.00 %) |
EPS: | SEK-0.150 |
Financial Reports:
No articles found.
AlzeCure Pharma AB (publ)
AlzeCure Pharma AB (publ), a pharmaceutical company, develops drug therapies for the treatment of severe diseases and conditions that affect the central nervous system. The company is developing drug candidates based on the NeuroRestore, Alzstatin, and Painless research platforms. Its pipeline drug candidates include ACD856, which is in phase I clinical trial for Alzheimer's disease, sleep disorders, traumatic brain injuries, and Parkinson's disease; ACD857, ACD679, and ACD680 for Alzheimer's disease; ACD440, a TRPV1 antagonist that has completed phase I clinical trial for neuropathic pain; and TrkA-NAM for osteoarthritic pain. The company was founded in 2012 and is based in Huddinge, Sweden.
About Live Signals
The live signals presented on this page help determine when to BUY or SELL NA. The signals have upwards of a 1-minute delay; like all market signals, there is a chance for error or mistakes.
The live trading signals are not definite, and getagraph.com hold no responsibility for any action taken upon these signals, as described in the Terms of Use. The signals are based on a wide range of technical analysis indicators